Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer | MicrobiomeTrials← Back to trialsNCT00445965
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
CompletedPHASE2INTERVENTIONAL
Trial Details
Start: 2006-01Est. Completion: 2023-02-01
Enrollment target: 78 participants Locations- Memorial Sloan Kettering Cancer Center, New York, New York, United States
Other microbiome trials you might be interested in
Cushing Disease
Background:
The pituitary gland produces hormones. A tumor in this gland can cause it to produce too much of the hormon…
Bethesda, United StatesEst. completion Jan 3, 2040
Fabry Disease
The aim of this randomized controlled study is to evaluate the effects of a six-week low-fermentable oligosaccharides, d…
Istanbul, Turkey (Türkiye)Est. completion Jan 30, 2027
Brain Neoplasm
Background:
Some people with brain tumors have seizures related to the tumor. This is called tumor-related epilepsy. Us…
Bethesda, United StatesEst. completion Jul 1, 2032